<DOC>
	<DOCNO>NCT02182193</DOCNO>
	<brief_summary>To assess pharmacokinetics relative bioavailability single dose BIBF 1120 soft gelatine capsule charge 1 vs. BIBF 1120 soft gelatine capsule charge 2 v BIBF 1120 drink solution healthy male subject respectively . To establish in-vitro-in-vivo correlation ( IVIVC ) oral soft gelatine capsule 150 mg BIBF 1120 healthy male volunteer ( feasible )</brief_summary>
	<brief_title>Safety Relative Bioavailability BIBF 1120 Soft Gelatine Capsules Charge 1 , BIBF 1120 Soft Gelatine Capsules Charge 2 BIBF 1120 Drinking Solution Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Healthy male subject determine result screen 2 . Signed write informed consent accordance GCP local legislation 3 . Age ≥21 ≤55 year 4 . Body Mass Index ≥18.5 kg/m2 ≤29.9 kg/m2 1 . Any finding medical examination ( include blood pressure , pulse rate ECG ) deviate normal clinical relevance 2 . History current gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunologic , hormonal disorder 3 . History relevant orthostatic hypotension , faint spell blackouts 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy excipients ) deem relevant trial judge investigator 7 . History bleed disorder include prolonged habitual bleeding , hematologic disease cerebral bleeding ( e.g . car accident ) commotio cerebri 8 . Intake drug long halflife ( &gt; 24 hour ) within 1 month prior administration 9 . Use drug might influence result trial within 14 day prior administration trial 10 . Participation another trial investigational drug within 2 month prior administration trial 11 . Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day 12 . Alcohol abuse ( &gt; 60 g/day ) 13 . Drug abuse 14 . Blood donation ( 150 mL within 4 week prior administration trial ) 15 . Excessive physical activity within 5 day prior administration trial 16 . Any laboratory value outside reference range clinical relevance 17 . Female gender 18 . Male subject refuse minimize risk female partner become pregnant first dose day 3 month completion study . Acceptable method contraception male volunteer include vasectomy less 3 month prior dose , barrier contraception medically accept contraceptive method . For female partner male volunteer , acceptable method contraception include intrauterine device , tubal ligation , hormonal contraceptive since least two month diaphragm spermicide</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>